GlassScriptPhysician profile
Steven Randall Brown
NPI 1730158585
$3,684.53
in general payments reported to CMS, 2019-2025
25 companies · $497 in 2025
The $497 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $116 · 2021: $394 · 2022: $776 · 2023: $833 · 2024: $674 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,003.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $659.67 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $534.06 | 2022-2025 | Qelbree, Qelbree |
| Pfizer INC. | $410.51 | 2019-2025 | |
| Neos Therapeutics, LP | $306.31 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Kaleo, INC. | $205.45 | 2019-2024 | Auvi-Q |
| Merck Sharp & Dohme LLC | $201.23 | 2019-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Ironshore Pharmaceuticals INC. | $197.36 | 2019-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $189.02 | 2019-2023 | |
| Glaxosmithkline, LLC. | $132.84 | 2019-2025 | Bexsero |
| Seqirus USA INC | $113.00 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Tris Pharma INC | $98.04 | 2021-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $92.48 | 2020-2025 | Elaprase |
| Astrazeneca Pharmaceuticals LP | $87.62 | 2021-2024 | Flumist Quadrivalent |
| Genentech USA, INC. | $83.58 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $64.44 | 2025 | Jornay Pm |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $55.69 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $50.77 | 2024 | |
| Alk-Abello, INC | $46.76 | 2025 | Neffy, Grastek, Odactra |
| Cognoa, INC. | $37.71 | 2022 | |
| Exeltis, USA INC. | $29.40 | 2023 | Slynd |
| Amneal Pharmaceuticals LLC | $26.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.19 | 2025 | Zoryve |
| Vertical Pharmaceuticals, LLC | $14.22 | 2025 | Relexxii |
| Shire North American Group INC | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.